[Intra and extra hepatic cholangiocarcinomas radiation therapy].

Area of Science:

• Gastroenterology and Oncology
• Digestive System Tumors
• Biliary Tract Cancers

Background:

• Cholangiocarcinomas are rare digestive tumors with a historically poor prognosis.
• Current evidence for adjuvant radiochemotherapy and radiotherapy in cholangiocarcinoma is limited, with no Phase III randomized controlled trials demonstrating benefit.
• Standard adjuvant treatment typically involves a 6-month course of capecitabine chemotherapy.

Purpose of the Study:

• To review the current evidence and established standards of care for cholangiocarcinoma treatment.
• To evaluate the role of different therapeutic modalities, including chemotherapy, radiochemotherapy, and stereotactic radiation therapy.
• To identify areas requiring further investigation, particularly in neoadjuvant and adjuvant settings.

Main Methods:

• Review of existing clinical trial data and treatment guidelines for cholangiocarcinoma.
• Analysis of the efficacy and toxicity profiles of various treatment approaches.
• Identification of validated treatment protocols for specific disease stages and patient subgroups.

Main Results:

• Adjuvant radiochemotherapy benefits have not been established through Phase III randomized controlled trials.
• Six months of capecitabine chemotherapy is the current standard of care in the adjuvant setting.
• Radiochemotherapy is validated for patients with R1 resection status; its use in neoadjuvant settings is not recommended due to insufficient evidence.

Conclusions:

• Chemotherapy and radiochemotherapy are validated for adjuvant or locally advanced cholangiocarcinoma.
• Stereotactic radiation therapy presents a potential future option but requires further evaluation in randomized trials due to significant digestive toxicities.
• Further research is crucial to define the optimal role of radiation in cholangiocarcinoma management.